Healthpeak Properties heads into the back half of June with the Street divided and options traders growing more cautious — even as the lending market remains exceptionally loose.
The most striking shift this week is in options positioning. Put demand has jumped sharply relative to recent norms. The put/call ratio hit 0.49, well above its 20-day average of 0.35 and running about 1.6 standard deviations above that mean. That's not an extreme reading by historical standards — the 52-week high is 1.59 — but it marks a clear break from the steady low-0.30s range that dominated the prior three weeks. Notably, the PCR was running above 0.50 back in mid-May when the stock was also under pressure, suggesting this pattern tends to emerge when macro or sector sentiment turns cautious. The stock itself is down 2% on the week and 1.7% on Monday alone, closing at $20.09.
The short interest story is noisier than it looks. The headline weekly figure shows SI climbing 12% over the past seven days to about 3.25% of the free float — but a single-session drop of 19% on June 16 complicates that read. The raw share count peaked near 28 million on June 15 before falling back sharply to around 22.6 million. What's clear is that short positioning had been building through late May and early June from a base of roughly 19 million shares, and has now partially reversed. The borrow market is not tight by any measure: availability is enormous at over 3,600% of short interest, meaning there are far more shares available to lend than are currently borrowed. Cost to borrow is just 0.50% — up roughly 28% on the week but still deep in "easy borrow" territory. There is no squeeze dynamic here.
Analyst activity is the more interesting tension. Morgan Stanley downgraded DOC on June 11, cutting it to Equal-Weight from Overweight while nudging the target to $22 from $20 — a "we still see some value but conviction has fallen" move from a bellwether house. Raymond James went further on June 17, reinstating coverage only at Market Perform. Against that, BMO Capital raised its target to $24 from $20 this week while keeping an Outperform rating — a notably bullish outlier. The mean analyst target sits at $21.28, implying roughly 6% upside from current levels, but the direction of travel from major names is cautious. The bear case centres on rising lab tenant credit risk, weak Q2 leasing, and FFOPS growth being revised toward flat-to-negative for 2026-2027. The bull case rests on a $148 million development pipeline that is roughly 80% pre-leased and expected to yield mid-7% at stabilisation. On valuation, EV/EBITDA is running near 14.8x, down modestly over the past month, which is neither cheap nor demanding for a healthcare REIT in the current rate environment.
One bright spot in the ORTEX factor scores is earnings surprise: DOC ranks in the 99th percentile on EPS surprise, reflecting a strong beat track record. The most recent earnings event in early May produced a one-day gain of nearly 19% and a five-day move of around 18%, which is a large reaction for a REIT and suggests the market was deeply under-positioned for the outcome. The next event is scheduled for August 4. On ownership, institutional concentration is high — BlackRock holds 10.6% and Vanguard entities collectively above 15% — meaning the register is dominated by passive and quasi-passive flows. JP Morgan Asset Management added nearly 11.7 million shares in the most recent reported period, the largest active change among top holders. Insider activity has been noise rather than signal: the sells in late May were tiny in dollar terms (under $2,500 each for most executives), reflecting routine share-withholding rather than conviction selling.
Closest peers offer some additional context. ARE (Alexandria Real Estate Equities), the most correlated US peer, fell 2.2% on the week — matching DOC's move almost exactly and suggesting sector-wide pressure rather than a DOC-specific story. HR, the highest-correlation peer, closed the week flat with a gain of 0.6%. The convergence of the Morgan Stanley downgrade, the rising PCR, and the one-month high in short interest from mid-May all pointing in the same direction — though the enormous availability in the lending market and BMO's aggressive $24 target leave open the question of how much of the caution is already priced in ahead of August earnings.
See the live data behind this article on ORTEX.
Open DOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
